Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review

被引:9
|
作者
Lopez-Lopez, Jose P. [1 ,2 ]
Gonzalez, Ana Maria [1 ]
Lanza, Paola [1 ]
Lopez-Jaramillo, Patricio [1 ,3 ]
机构
[1] Univ Santander UDES, MASIRA Res Inst, Bucaramanga, Santander, Colombia
[2] Pontificia Univ Javeriana, Hosp Univ San Ignacio, Dept Internal Med, Cardiol Unit, Bogota, Colombia
[3] Univ Santander UDES, MASIRA Res Inst, Fac Ciencias Salud, Bloque G,Piso 6, Bucaramanga, Santander, Colombia
关键词
polypill; cardiovascular disease; hypertension; dyslipidemia; major cardiovascular events; DOSE COMBINATION TREATMENT; HIGH-RISK; BLOOD-PRESSURE; STRATEGY; TRIAL; DRUGS;
D O I
10.2147/VHRM.S421024
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background: Higher medication adherence reduces the risk of new cardiovascular events. However, there are individual and health system barriers that lead to lower adherence. The polypill has demonstrated benefits in cardiovascular morbidity and mortality mainly driven by an increase in adherence. We aim to evaluate the impact of the polypill on adherence to cardiovascular medication, its efficacy and safety in cardiovascular disease (CVD) prevention. Methods: A systematic review following PRISMA guidelines was conducted. Databases were searched from January 2003 to December 2022. We included randomized, pragmatic, or real-world clinical trials and observational studies. The primary outcome was medication adherence, secondary outcomes were efficacy in cardiovascular disease in primary and secondary prevention and safety. Results: From the 490 publications screened, 13 met the inclusion criteria and were incorporated into a comparative table Of those included, 70% were randomized controlled trials (RCTs) and 53.8% focused on secondary prevention. Most of the studies received a high and moderate quality rating. Self-report, pill counting and, the Morisky scale were the most frequent methods to evaluate adherence (84.6%). Compared with standard medication, the polypill improved overall medication adherence by 13%, with percen-tages ranging from 7.6% to 34.9%. Moreover, a potential benefit was also observed in reducing Major Adverse Cardiovascular Events (MACE), particularly in secondary prevention studies, with hazard ratios ranged between 0.43 to 0.76. Compared to standard care, the profile of side effects was similar. Conclusion: The polypill is an effective, safe, and practical strategy to improve adherence in people at risk of CVD. Although there is a demonstrated benefit in reducing MACE, predominantly in secondary prevention, there are still gaps in its efficacy in primary prevention and reducing total mortality. Therefore, the importance of obtaining long-term results of the polypill effect and how this strategy can be implemented in real practice.
引用
收藏
页码:605 / 615
页数:11
相关论文
共 50 条
  • [31] Polypill for Cardiovascular Disease Prevention in an Underserved Population
    Munoz, Daniel
    Uzoije, Prince
    Reynolds, Cassandra
    Miller, Roslynn
    Walkley, David
    Pappalardo, Susan
    Tousey, Phyllis
    Munro, Heather
    Gonzales, Holly
    Song, Wenliang
    White, Charles
    Blot, William J.
    Wang, Thomas J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (12) : 1114 - 1123
  • [32] Statins alone or polypill for primary prevention of cardiovascular diseases
    Hasani-Ranjbar, Shirin
    Ejtahed, Hanieh-Sadat
    JOURNAL OF DIABETES AND METABOLIC DISORDERS, 2016, 15
  • [33] Effectiveness of multifactorial interventions in primary health care settings for primary prevention of cardiovascular disease: A systematic review of systematic reviews
    Alvarez-Bueno, Celia
    Cavero-Redondo, Ivan
    Martinez-Andres, Maria
    Arias-Palencia, Natalia
    Ramos-Blanes, Rafael
    Salcedo-Aguilar, Fernando
    PREVENTIVE MEDICINE, 2015, 76 : S68 - S75
  • [34] Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients
    Ros-Castello, Victoria
    Natera-Villalba, Elena
    Gomez-Lopez, Ana
    Sanchez-Sanchez, Arantxa
    Luis Chico-Garcia, Juan
    Garcia-Madrona, Sebastian
    Vera-Lechuga, Rocio
    Matute-Lozano, Consuelo
    de Felipe Mimbrera, Alicia
    Cruz-Culebras, Antonio
    Alonso-Canovas, Araceli
    Masjuan, Jaime
    CEREBROVASCULAR DISEASES EXTRA, 2020, 10 (03): : 166 - 173
  • [35] Usefulness of the Polypill for the Prevention of Cardiovascular Disease and Hypertension
    Steven G. Chrysant
    George S. Chrysant
    Current Hypertension Reports, 2016, 18
  • [36] Statins alone or polypill for primary prevention of cardiovascular diseases
    Shirin Hasani-Ranjbar
    Hanieh-Sadat Ejtahed
    Journal of Diabetes & Metabolic Disorders, 15 (1)
  • [37] Global cardiovascular risk assessment in the primary prevention of cardiovascular disease in adults: systematic review of systematic reviews
    Collins, Dylan R. J.
    Tompson, Alice C.
    Onakpoya, Igho J.
    Roberts, Nia
    Ward, Alison M.
    Heneghan, Carl J.
    BMJ OPEN, 2017, 7 (03):
  • [38] Evaluating patients' satisfaction and preferences with a secondary prevention cardiovascular polypill: the Aurora Study
    Cosin-Sales, Juan
    Murcia-Zaragoza, Jose M.
    Pereyra-Rico, Hector O.
    de la Guia-Galipienso, Fernando
    Hermans, Kurt
    Rubio, Gabriel
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (13) : 975 - 985
  • [39] Access and adherence to medications for the primary and secondary prevention of atherosclerotic cardiovascular disease in Singapore: a qualitative study
    Koh, Joel Jun Kai
    Cheng, Rui Xiang
    Yap, Yicheng
    Haldane, Victoria
    Tan, Yao Guo
    Teo, Krichelle Wei Qi
    Srivastava, Aastha
    Ong, Pei Shi
    Perel, Pablo
    Legido-Quigley, Helena
    PATIENT PREFERENCE AND ADHERENCE, 2018, 12 : 2481 - 2498
  • [40] Prospects for a Cardiovascular Disease Prevention Polypill
    Dabhadkar, Kaustubh C.
    Kulshreshtha, Ambar
    Ali, Mohammed K.
    Narayan, K. M. Venkat
    ANNUAL REVIEW OF PUBLIC HEALTH, VOL 32, 2011, 32 : 23 - 38